Fate Therapeutics (FATE) EBIT Margin (2016 - 2025)
Historic EBIT Margin for Fate Therapeutics (FATE) over the last 14 years, with Q3 2025 value amounting to 1995.12%.
- Fate Therapeutics' EBIT Margin fell 2912500.0% to 1995.12% in Q3 2025 from the same period last year, while for Sep 2025 it was 2448.24%, marking a year-over-year decrease of 9861800.0%. This contributed to the annual value of 1542.63% for FY2024, which is 12427700.0% down from last year.
- Latest data reveals that Fate Therapeutics reported EBIT Margin of 1995.12% as of Q3 2025, which was down 2912500.0% from 1938.54% recorded in Q2 2025.
- In the past 5 years, Fate Therapeutics' EBIT Margin ranged from a high of 48.48% in Q1 2023 and a low of 6705.79% during Q2 2023
- Moreover, its 5-year median value for EBIT Margin was 665.73% (2024), whereas its average is 1589.41%.
- Its EBIT Margin has fluctuated over the past 5 years, first plummeted by -62577400bps in 2023, then skyrocketed by 60400600bps in 2024.
- Quarter analysis of 5 years shows Fate Therapeutics' EBIT Margin stood at 406.48% in 2021, then surged by 64bps to 145.23% in 2022, then plummeted by -1875bps to 2868.44% in 2023, then fell by -16bps to 3319.78% in 2024, then skyrocketed by 40bps to 1995.12% in 2025.
- Its last three reported values are 1995.12% in Q3 2025, 1938.54% for Q2 2025, and 2534.07% during Q1 2025.